Last ¥4,673 JPY
Change Today +3.00 / 0.06%
Volume 1.4M
As of 2:00 AM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

takeda pharmaceutical co ltd (4502) Snapshot

Open
¥4,695
Previous Close
¥4,670
Day High
¥4,701
Day Low
¥4,670
52 Week High
12/10/13 - ¥5,170
52 Week Low
07/31/13 - ¥4,375
Market Cap
3.7T
Average Volume 10 Days
1.7M
EPS TTM
¥130.89
Shares Outstanding
789.7M
EX-Date
09/26/14
P/E TM
35.7x
Dividend
¥180.00
Dividend Yield
3.85%
Current Stock Chart for TAKEDA PHARMACEUTICAL CO LTD (4502)

Related News

No related news articles were found.

takeda pharmaceutical co ltd (4502) Details

Takeda Pharmaceutical Company Limited is engaged in supplying pharmaceutical products worldwide. The company provides products in various therapeutic areas, including cardiovascular and metabolic, oncology, central nervous system, respiratory and immunology, and gastrointestinal and genitourinary, as well as vaccines. It is also involved in the manufacture and sale of OTC drugs and quasi-drugs, reagents, clinical diagnostics, and chemical products. The company has strategic alliance with MacroGenics, Inc. to develop DART for treatment of autoimmune disorders. Takeda Pharmaceutical Company Limited was founded in 1781 and is based in Osaka, Japan.

31,225 Employees
Last Reported Date: 06/27/14
Founded in 1781

takeda pharmaceutical co ltd (4502) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

takeda pharmaceutical co ltd (4502) Key Developments

Takeda Pharmaceutical Company Limited Announces New Assignment of Directors

Takeda Pharmaceutical Company Limited announced the new assignment of directors, effective June 27, 2014. Yasuchika Hasegawa has been newly assigned as chairman of the board from the previous designation of president. Christophe Weber has been newly assigned as representative director and president from the previous designation of corporate officer. Shinji Honda has been newly assigned as senior managing director from the previous designation of director. François-Xavier Roger has been newly assigned as director from the previous designation of corporate officer. Masahiro Sakane, Councilor, Komatsu Ltd. has been newly assigned as outside director.

Takeda Pharmaceutical Company Limited Announces the Availability of Hypertension Drugs

Takeda Pharmaceutical Company Limited has announced the availability of Zacras combination tablets, a fixed-dose combination, or FDC, of azilsartan and amlodipine besylate hydrochloride, and Azilva tablets 10mg, indicated for treatment of hypertension. Zacras is a tablet administrated orally once daily and has two dosage strengths, 'Zacras Combination Tablets LD' and 'Zacras Combination Tablets HD' which contain 20mg azilsartan /2.5mg amlodipine, and 20mg azilsartan /5mg amlodipine respectively. Azilva tablets 10 mg is the addition of a new dosage strength to already-marketed Azilva Tablets 20mg and 40 mg. Discovered by Takeda, azilsartan is a potent and lasting angiotensin II receptor blocker (ARB) that lowers blood pressure by inhibiting the action of angiotensin II, a vasopressor hormone. Amlodipine is a calcium channel blocker (CCB) having a hypotensive action by blocking inward calcium ion channels mainly in vascular smooth-muscle cells, resulting in peripheral arteriolar vasodilation. In a phase III clinical trial, the anti-hypertensive effect in diastolic blood pressure in the sitting position as the primary endpoint, of Zacras was statistically significant compared to monotherapy with either azilsartan or amlodipine.

Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals USA., Inc. Announce the Availability of ENTYVIO for Ulcerative Colitis and Crohn's Disease

Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals USA., Inc. have announced the availability of a new biologic therapy, ENTYVIO, indicated for the treatment of adults with moderately to severely active ulcerative colitis, or UC, and Crohn's disease. Entyvio is now available to US healthcare providers for inducing and maintaining clinical response and remission, improving endoscopic appearance of the mucosa, and achieving corticosteroid-free remission in adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. Entyvio is also indicated for achieving clinical response and remission, and achieving corticosteroid-free remission in adult patients with moderately to severely active CD who have had an inadequate response with, lost response to, or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4502:JP ¥4,673.00 JPY +3.00

4502 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,404 JPY +22.00
Baxter International Inc $76.11 USD -0.41
Becton Dickinson and Co $117.84 USD -0.77
Bristol-Myers Squibb Co $48.92 USD -0.20
Merck KGaA €63.41 EUR -0.02
View Industry Companies
 

Industry Analysis

4502

Industry Average

Valuation 4502 Industry Range
Price/Earnings 35.2x
Price/Sales 2.2x
Price/Book 1.5x
Price/Cash Flow 15.0x
TEV/Sales 1.3x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKEDA PHARMACEUTICAL CO LTD, please visit www.takeda.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.